US 12,035,959 B2
Devices, systems and methods for evaluation and feedback of neuromodulation treatment
Sowmya Ballakur, Ithaca, NY (US); Robert J. Beetel, Woodside, CA (US); Paul Friedrichs, Belmont, CA (US); David Herzfeld, Grafton, WI (US); Andrew Wu, Los Altos Hills, CA (US); Denise Zarins, Saratoga, CA (US); and Mark S. Leung, Duncan (CA)
Assigned to Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed by Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed on May 7, 2021, as Appl. No. 17/314,894.
Application 17/314,894 is a continuation of application No. 16/219,856, filed on Dec. 13, 2018, granted, now 11,006,999.
Application 16/219,856 is a continuation of application No. 15/665,787, filed on Aug. 1, 2017, granted, now 10,179,020, issued on Jan. 15, 2019.
Application 15/665,787 is a continuation of application No. 15/136,109, filed on Apr. 22, 2016, granted, now 9,750,560, issued on Sep. 5, 2017.
Application 15/136,109 is a continuation of application No. 14/718,843, filed on May 21, 2015, granted, now 9,345,530, issued on May 24, 2016.
Application 14/718,843 is a continuation of application No. 13/281,269, filed on Oct. 25, 2011, granted, now 9,066,720, issued on Jun. 30, 2015.
Claims priority of provisional application 61/528,684, filed on Aug. 29, 2011.
Claims priority of provisional application 61/528,108, filed on Aug. 26, 2011.
Claims priority of provisional application 61/528,091, filed on Aug. 26, 2011.
Claims priority of provisional application 61/406,531, filed on Oct. 25, 2010.
Prior Publication US 2021/0259760 A1, Aug. 26, 2021
Int. Cl. A61B 18/12 (2006.01); A61B 18/10 (2006.01); A61B 18/14 (2006.01); A61F 7/12 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61F 7/00 (2006.01)
CPC A61B 18/1206 (2013.01) [A61B 18/10 (2013.01); A61B 18/1492 (2013.01); A61F 7/12 (2013.01); A61B 2017/00075 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00505 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00648 (2013.01); A61B 2018/00672 (2013.01); A61B 2018/00678 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00761 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00797 (2013.01); A61B 2018/00815 (2013.01); A61B 2018/00821 (2013.01); A61B 2018/00863 (2013.01); A61B 2018/00875 (2013.01); A61F 2007/0093 (2013.01); A61F 2007/126 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for providing feedback related to a neuromodulation treatment, the method comprising:
determining an unexpected or aberrant condition associated with the neuromodulation treatment occurred during administration of the neuromodulation treatment;
based on determining the unexpected or aberrant condition occurred, obtaining a set of treatment data corresponding to the neuromodulation treatment;
evaluating the set of treatment data in view of one or more criteria to determine appropriate feedback; and
providing the appropriate feedback based on the evaluation.